We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
AbbVie’s Qulipta (atogepant), already approved for prevention of episodic migraine, has released new phase 3 data that also support its preventive effect for chronic migraine. Read More
Armed with positive phase 3 data, Venatorx Pharmaceuticals will ask regulators to approve its investigational combination antibiotic, cefepime-taniborbactam, as a treatment for complicated urinary tract infections (cUTI) in adults. Read More
Efanesoctocog alfa, a bioengineered clotting factor being co-developed by Sanofi and Sobi, practically eliminated bleeding episodes in patients with hemophilia A who took it as a prophylactic weekly injection. Read More
Despite pushing for greater clinical trial participation of minority patients via a five-year action plan, the FDA’s efforts appear to have made little difference for Black patients, the latest analysis has found. Read More
Novartis and Voyager Therapeutics have joined forces to develop adenovirus viral vectors (AAV) that could cross the blood-brain barrier, potentially delivering gene therapy deep into the brain. Read More
Gilead Sciences is touting a phase 3 win for its drug-antibody conjugate Trodelvy (sacituzumab govitecan-hziy), saying it significantly improved progression-free survival in women with metastatic, treatment-resistant breast cancer. Read More
Eli Lilly’s Olumiant (baricitinib), a powerful anti-inflammatory used to treat rheumatoid arthritis, has once again proven its mettle against COVID-19. Read More
The nonprofit generic drugmaker Civica said that it’s going to manufacture three different insulin biosimilars that, if approved, will be distributed at prices that are “significantly lower” than the cost of insulin products that are currently available on the market. Read More